Gaithersburg, MD - On March 17, 2011, the Food and Drug Administration's Neurological Devices Panel endorsed the premarket approval application (PMA) for Novocure's NovoTTF-100A Treatment Kit - a novel, non-invasive device that blasts glioblastoma brain tumors with an electrical field.

WEST PALM BEACH, FL - More than 800 runners and walkers joined forces on Sunday, March 6, 2022 for the 2nd Annual Florida Brain Cancer 5k Run/Walk, and together raised more than $146,000 to benefit brain cancer research projects and collaborations through Accelerate Brain Cancer Cure.

Anne Feeley is a brain cancer survivor, founder of Brains on Bikes and good friend of Accelerate Brain Cancer Cure.

Accelerate Brain Cancer Cure recently funded Dr. Karen Aboody, a pioneering stem cell researcher at the City of Hope Medical Center in Duarte, California. 

She is working on a revolutionary new cancer treatment for the very worst brain tumors called glioblastomas (GBM).  These types of tumors are so invasive that until now there's been no way to get large enough amounts of chemotherapy through the blood-brain barrier. 

A University of Alabama at Birmingham study has identified a gene deletion in nearly 25 percent of all glioblastoma cases that is believed to be responsible for poor patient outcomes. The discovery could lead to better diagnosis and targeted treatments with drugs that are currently available.

Duke Vaccine Extends Life for Brain Cancer Patients

October 4, 2021 - A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer, according to a study from researchers at Duke University Medical Center and The University of Texas MD Anderson Cancer Center.

The vaccine also knocks out a troublesome growth factor that characterizes the most aggressive form of the disease.

Main Image: 

2010 Annual Scientific Retreat

Thursday, September 30, 2021 to Friday, October 1, 2021

Thursday, September 308:30 – 9:00 – Welcome, Chairman’s Remarks, and Introductions

Karen Avery
Director of Foundation Relations, Smithsonian Institution

Steve Case
Chairman, Accelerate Brain Cancer Cure

Max Wallace
CEO, Accelerate Brain Cancer Cure

9:00 – 9:30 – Clinical Treatment of GBM – Where Are We and Where Do We Need to Go?

Mike Prados
Director of Translational Research in Neuro-Oncology, UCSF

9:45 – 12:00 – Molecular Elucidation of Brain Cancer

Lynda Chin
Professor of Dermatology, Harvard Medical School

Stephen Friend
President, Co-Founder and Director, Sage BioNetworks

Markus Bredel
Director, Radiation Oncology Brain Tumor Laboratory, UAB

1:00– 2:45 – New Strategies and Opportunities in Targeting GBM

Paul Mischel
Professor of Pathology, UCLA

Heidi Phillips
Senior Scientist, Genentech

David Schenkein
CEO, Agios Pharmaceuticals

3:00 – 4:15    

Martin Brown
Director, Division of Radiation and Cancer Biology, Stanford

Graeme Bilbe
Global Head of Neuroscience Research, Novartis

Friday, October 18:30 – 9:00 – Integration of Clinical Genomics into the Discovery and Development of Novel Cancer Therapies

Neil Gibson
Vice President and Chief Scientific Officer, Pfizer Oncology

9:00 – 11:00 – New Initiatives in Preclinical Animal Models for GBM

Terry Van Dyke
Chief, Mouse Cancer Genetics Program, NCI

David James
Professor of Neurological Surgery, UCSF

Neal Goodwin
The Jackson Laboratories

11:00 – 11:30 – New Clinical Trials in Brain Cancer

Karen Aboody
Associate Professor, Neurosciences, City of Hope

11:30 – 11:45 – Closing Remarks

Max Wallace
CEO, Accelerate Brain Cancer Cure


Share |

Join us in our fight for a cure!